Compounds covered
33
15
TitrateLab/Vendors/GYC vs Lilipeptide
▸ Vendor comparison
GYC vs Lilipeptide
A head-to-head, evidence-first comparison of GYC and Lilipeptide — built from 349 and 322 tracked third-party lab records respectively. Exact result/date/dose duplicates are collapsed in the quality comparison so one certificate arriving twice cannot count twice. TitrateLab does not rank or endorse vendors and takes no payment for placement.
Shareable compound comparison
Peptide Battles
All compounds · deduplicated reports
Evidence snapshot
Evidence coverage
Tested by Janoshik
51.9%318 reports
0.0%322 reports
Fill measured
54.4%318 reports
1.6%322 reports
Endotoxin tested
4.4%318 reports
7.5%322 reports
Purity & identity
Average purity
99.7%249 tests
99.2%306 tests
Purity below 90%
0.0%249 tests
1.0%306 tests
Compound not detected
1.19%252 results
4.67%321 results
Fill results
Underfilled >15%
0.6%173 tests
0.0%5 tests
Fill within ±10%
48.0%173 tests
0.0%5 tests
Overfilled >10%
50.9%173 tests
100.0%5 tests
Flags & missing data
Endotoxin failures
28.6%14 tests
0.0%24 tests
Unknown / 0% results
46.9%318 reports
98.4%322 reports
Recency
Latest test
2026-08-09
2026-09-15
How these metrics are calculated
Lab reports
Deduplicated published reports attributed to this vendor.
Compounds covered
Distinct normalized compound names represented in the counted reports.
Tested by Janoshik
Share of counted reports performed by Janoshik. Coverage, not quality.
Fill measured
Share of counted reports with a classifiable measurement against the printed fill amount. Finnrick batch-claim rows are excluded.
Endotoxin tested
Share of reports carrying a classifiable endotoxin outcome. Coverage, not a pass rate.
Average purity
Mean of positive purity tests. Identity failures are counted separately.
Purity below 90%
Share of positive purity results measured below 90%. Exact-zero identity failures are counted separately.
Compound not detected
Labelled compound not detected, as a share of reports that reported a purity outcome.
Underfilled >15%
Share of fill tests measured more than 15% below the printed amount. Vendor batch claims are never used.
Fill within ±10%
Share of classifiable fill tests measured within 10% above or below the printed amount.
Overfilled >10%
Share of classifiable fill tests measured more than 10% above the printed amount.
Endotoxin failures
Share of classifiable endotoxin outcomes assigned to the canonical failure tier.
Unknown / 0% results
Reports without a positive purity result or a classifiable printed-fill result; a report missing both is counted once, and exact 0% results are included.
Latest test
Most recent valid test date at or before today. Recency is context, not quality.
Observed third-party reports only. These figures describe tested batches, not every lot sold, and do not rank or endorse either vendor.
Share this comparison
A card carrying these exact figures and their denominators, dated, with the canonical link. Independent evidence — not certification or endorsement.
Compound and dose comparison
Choose a compound above to compare evidence quality for the product that actually matters.
Compare the same compound—and the same labeled dose.
Unlock Pro comparison
Pro unlocks deduplicated purity, fill accuracy, identity-failure, Janoshik, endotoxin, and recency evidence for this exact vendor pair.
Most-tested compounds
The peptides each vendor has the most independent certificates for. Click a compound to see its research hub.
Explore further
These figures are purity analytics aggregated from independent third-party certificates of analysis, not vendor claims. Purity is measured on the specific batches submitted for analysis and is not a guarantee for any other lot. This is research-use-only information; TitrateLab does not rank or endorse vendors and this is not a recommendation to purchase or use any product.
